Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Polyphenon E - Aresus Pharma/Epitome Pharmaceuticals

Drug Profile

Polyphenon E - Aresus Pharma/Epitome Pharmaceuticals

Alternative Names: Polyphenon E; SB 03; Sinecatechins; Veregen

Latest Information Update: 31 Mar 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsui Norin; Polyphenon Pharma
  • Developer Emory University; Maastricht University; MediGene AG; Polyphenon Pharma; SynCore Biotechnology; Triton Pharma; Will-Pharma
  • Class Antineoplastics; Antivirals; Catechins; Herbal medicines
  • Mechanism of Action Antioxidants; Immunostimulants; Viral fusion protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Genital warts
  • Phase II/III Basal cell cancer
  • Phase II Prostatic intraepithelial neoplasia
  • No development reported Bladder cancer; Head and neck cancer
  • Discontinued Actinic keratosis; Angina pectoris; Chronic lymphocytic leukaemia

Most Recent Events

  • 24 Mar 2020 Azanta has been acquired by Norgine
  • 01 Jun 2019 Adverse events and efficacy data from a phase I trial in Head and neck cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 09 Apr 2019 Polyphenon E licensed to Aresus Pharma in World (excluding USA)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top